Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Pharmacol Biochem Behav. 2008 Oct;90(4):569–577. doi: 10.1016/j.pbb.2008.04.017

Figure 3. Effects of subchronic PCP administration (PN7, 9 and 11) on PPI of acoustic startle.

Figure 3

PCP treatment (10 mg/kg) treatment on PN7, 9, and 11 results in a deficit in PPI of acoustic startle as measured on PN24–26. Pretreatment on PN7, 9, and 11 with olanzapine (1 mg/kg) or risperidone (0.25 mg/kg) inhibits the PCP-induced deficit in PPI of acoustic startle. *p<0.05 vs. saline (one-way ANOVA with Bonferroni’s post hoc test). N=8 in both control and experimental groups.